日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

[225Ac]Ac- 和 [111In]In-DOTA-曲妥珠单抗治疗诊断对:HER2 阳性人乳腺癌异种移植 NRG 小鼠的体外细胞剂量和细胞毒性以及体内肿瘤和正常组织摄取

Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan, Raymond M Reilly

Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

按照良好生产规范 (GMP) 配制用于制备 [111In]In-BnDTPA-曲妥珠单抗-NLS 注射剂的试剂盒:用于 HER2 阳性乳腺癌的成像和迈特纳-俄歇电子 (MAE) 放射免疫治疗的治疗诊断剂

Conrad Chan, Vanessa Prozzo, Sadaf Aghevlian, Raymond M Reilly

Podoplanin Drives Motility of Active Macrophage via Regulating Filamin C During Helicobacter pylori Infection

在幽门螺杆菌感染期间,足蛋白通过调节丝状蛋白C驱动活性巨噬细胞的运动。

Cheok, Yi Ying; Tan, Grace Min Yi; Fernandez, Keith Conrad; Chan, Yee Teng; Lee, Chalystha Yie Qin; Cheong, Heng Choon; Looi, Chung Yeng; Vadivelu, Jamuna; Abdullah, Suhailah; Wong, Won Fen

Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT

利用PET/CT成像技术研究64Cu-NOTA-pertuzumab F(ab')2在肿瘤HER2表达变化(与曲妥珠单抗治疗反应相关)方面的开发和临床前研究

Karen Lam ,Conrad Chan ,Raymond M Reilly